Several monoclonal antibodies blocking immune checkpoints such as Programmed cell Death-1 (PD-1), Programmed Death-Ligand 1 (PD-L1), Cytotoxic-T-Lymphocyte Antigen-4 (CTLA-4) have already been approved for the treatment of different types of cancer. This evidence concerns the gene CTLA4 and cancer.